Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 29, 2025
Data Byte
EMA’s CHMP snubs donanemab, even for APOE4 non-carriers
Lilly to seek re-examination. Also in March meeting, CHMP backs label expansions for Opdivo, Tevimbra and more
BioCentury | Mar 1, 2025
Data Byte
EMA’s CHMP reaffirms its decision to back Leqembi for Alzheimer’s
Regeneron’s bispecific, Krystal’s gene therapy, and 16 label extensions also among positive opinions issued at committee’s February meeting
BioCentury | Feb 20, 2025
Emerging Company Profile
Switch: Precision siRNA knockdown
San Francisco-based biotech is pursuing CNS diseases with three-stranded siRNAs that can target specific cell types within a tissue
BioCentury | Dec 19, 2024
Discovery & Translation
Science Spotlight: Platelets as targeted protein degraders
BioCentury’s roundup of translational innovations also includes ribonucleoproteins delivery and fine-tuning TCR specificity
BioCentury | Nov 16, 2024
Data Byte
EMA’s CHMP finds path to Leqembi nod, backs three other new drugs
Eleven label expansions also among committee’s November recommendations
BioCentury | Nov 12, 2024
Politics, Policy & Law
Prepping for Trump & Alzheimer’s ethics: a BioCentury podcast
Also on BioCentury This Week: AZ’s China trouble and the myths that shape perceptions in the biopharma sector
BioCentury | Nov 8, 2024
Product Development
The evolving picture of ARIA risk and APOE4 status in Alzheimer’s
As data on amyloid-targeting drugs have emerged, pressing questions—and answers—about their leading safety concern have come into focus
BioCentury | Nov 7, 2024
Product Development
The ethics of Alzheimer's trials: more to the story
Companies, academics, advocates push back on claims they should have disclosed genotype to Alzheimer's trial participants
BioCentury | Nov 6, 2024
Product Development
Alzheimer’s roundup: Clinical progress and setbacks at CTAD
Readouts showcase promise of Roche’s brainshuttle; plus mixed results from Lilly, Lexeo and Anavex
BioCentury | Sep 10, 2024
Deals
Deals report: Roivant sets up Pulmovant to advance hypertension therapy
Plus: Candid joining two VC-backed start-ups to focus on autoimmune bispecifics, and updates from Eli Lilly, Haya, Genetic Leap and more
Items per page:
1 - 10 of 226